Document:

Q2 2014 Exhibit 10.1

Exhibit 10.1

[Execution Copy]

NINTH AMENDED AND RESTATED SECURED PROMISSORY NOTE

(For Revolving Line of Credit, Advances and Guaranteed Obligations)

	

(Up to) $4,500,000

	
April 29, 2014

	
Los Angeles, California    

$1,513,309 (current balance under Revolving Line of Credit)

$2,781,561 (total Unpaid Balance)

For Value Received, the undersigned MyMedicalRecords, Inc. (formerly mymedicalrecords.com, Inc.), a Delaware corporation ("Subsidiary") and  MMRGlobal, Inc.
(formerly MMR Information Systems, Inc., formerly Favrille, Inc.), a Delaware corporation ("Parent") (together, "Borrower"), promises to pay to the order of The RHL
Group, Inc., a California corporation ("Lender"), the sum of up to Four Million Five Hundred Thousand Dollars ($4,500,000) on a revolving basis (sometimes referred to as a
"Reserve Line of Credit" herein) with interest from the date of disbursement on the Unpaid Balance, as that term is used herein, and defined below, from time to time outstanding.
Capitalized terms used herein without definition shall, unless otherwise indicated, have the meanings given to such terms in the Security Agreement dated July 31, 2007, as amended on June
30, 2012 under the First Amended Security Agreement (together, the "Security Agreement"), which grants certain security interests in the Collateral owned by Borrower, as therein
defined. Borrower and Lender agree that the terms of this Ninth Amended and Restated Secured Promissory Note ("Ninth Amended Note") apply to the Reserve Line of Credit.

This Ninth Amended Note is intended to update and amend that certain Secured Promissory Note (the "Original Note") dated July 30, 2007, as amended by the Amended and
Restated Secured Promissory Note (the "First Amended Note"), dated August 23, 2007, and as further amended by the Second Amended and Restated Secured Promissory Note
(the "Second Amended Note") dated August 1, 2008, which was modified by the Allonge dated January 27, 2009 (the "Allonge"), which notes were approved by the
Borrower's Board of Directors by resolutions dated July 23, 2007, August 30, 2007 and June 2, 2008, respectively, which was further amended by the Third Amended and Restated Secured
Promissory Note dated April 29, 2009 (the "Third Amended Note"), which was further amended by the Fourth Amended and Restated Secured Promissory Note dated April 29,
2010(the "Fourth Amended Note"), which was further amended by the Fifth Amended and Restated Secured Promissory Note dated April 29, 2011 (the "Fifth Amended
Note") and further amended by the Sixth Amended and Restated Secured Promissory Note dated April 29, 2012 (the "Sixth Amended Note"), which was further amended by
the Seventh Amended and Restated Secured Promissory Note (the "Seventh Amended Note") dated July 30, 2012, which was further amended by the Eighth Amended and
Restated Secured Promissory Note (the "Eighth Amended Note") dated April 29, 2013.  As stated therein, the Original Note, the First Amended Note, the Second Amended Note,
the Third Amended Note, the Fourth Amended Note, the Fifth Amended Note the Sixth Amended Note,

	

PROMISSORY NOTE

	
Page 1 of 8      

the Seventh Amended Note, and the Eighth Amended Note provided for increases, if
necessary, in the amount of the Reserve Line of Credit, and the terms of the Security Agreement provide for that agreement to apply to advances in excess of the therein stated
"Amount".  The terms of the Security Agreement shall be deemed to apply to, and a security interest is hereby granted to the Lender, for all advances made, under this Ninth
Amended Note to the same extent, validity, security and priority as to advances under the Original Note, the First Amended Note, the Second Amended Note, the Third Amended Note, the
Fourth Amended Note, the Fifth Amended Note, the Sixth Amended Note, the Seventh Amended Note, and the Eighth Amended Note, with the exception that the Seventh Amended Note, the
Eight Amended Note, and this Ninth Amended Note and the Security Agreement, are deemed to apply to the Parent as well as to the Subsidiary.

The original of the First Amended Note, Second Amended Note, Third Amended Note, including the Allonge, Fourth Amended Note, Fifth Amended Note, Sixth Amended Note, Seventh
Amended Note, and Eighth Amended Note have been marked as "superseded".  If and only if the Ninth Amended Note is deemed unenforceable, or if the Security Agreement is,
for any reason, deemed not to apply to the Ninth Amended Note, then the terms of the Eighth Amended Note, (or the Seventh Amended Note, Sixth Amended Note, the Fifth Amended Note
or the Fourth Amended Note or the Third Amended Note or the Second Amended Note including the Allonge, or the First Amended Note or the Original Note, and the Guaranty previously
signed by the Parent, as the case may be and if necessary) shall be deemed reinstated to the extent necessary to: (a) repay the advances of the Lender, and (b) provide for security to the Lender.

The term "Unpaid Balance" shall mean all of the following: (a) the funds actually lent to the Borrower, or either the Parent or the Subsidiary, including interest, fees, and costs
thereon (which includes reasonable legal expenses and costs of Lender in connection with this Ninth Amended Note) ; (b) any funds paid or advanced for the benefit of the Borrower at the
request of Borrower to third parties, including charges made on the Lender's credit or charge cards, or credit or charge cards for which Lender is liable (exclusive of interest on such charges)
("Credit Card Advances") on or after July 23, 2007, (c) subject to the last sentence of this paragraph, any amounts guaranteed by the Lender at the request of Borrower, for which
the guarantees are still outstanding (including any personal guarantees by Robert H. Lorsch as approved by the Board of Directors), (d) unpaid consulting fees, salary or expenses accrued or
owed to Lender.  However, any amounts guaranteed by the Lender and unpaid consulting fees shall not be included in the balance under the Revolving Line of Credit, but shall reduce the
balance available under the Reserve Line of Credit.    

The entire Unpaid Balance shall be due and payable at the end of each calendar month, provided however, that if the Borrower is not otherwise in default under the Original Note, the
First Amended Note, the Second Amended Note, the Third Amended Note, the Fourth Amended Note, the Fifth Amended Note, the Sixth Amended, the Seventh Amended Note, the Eighth
Amended Note, or the Ninth Amended Note, or the Security Agreement, as amended from time to time, the Reserve Line of Credit shall continue in existence for the next succeeding month,
and payment of the full Unpaid Balance shall be similarly deferred.  However, notwithstanding any other provision in this Note: (a) the obligation to pay interest on a monthly basis, and the
obligation to pay the Credit Card Advances, if any, shall continue to be due and payable on a

	

PROMISSORY NOTE

	
Page 2 of 8      

monthly basis, and (b) unless otherwise agreed in writing by Lender, the entire unpaid balance
shall be due and owing, without extension, April 29, 2015 (the "Final Maturity Date").

The monthly payment shall not include any interest for amounts guaranteed by the Lender unless the Lender has performed on the guarantee, whether by payment or otherwise, except
that on the Final Maturity Date the Borrower must pay all amounts due and any amounts due under any still then outstanding guarantees of Lender at the option of Lender.  Notwithstanding
anything to the contrary in this Note, or any of the predecessor notes that have been marked as "superseded", the Subsidiary shall pay at least $1,000 per month, starting on
August 1, 2013, to the holder of this Note.

Upon the occurrence of an Event of Default, as defined in this Note or the Security Agreement, the Final Maturity Date shall be accelerated as against the Parent, the Subsidiary, or both,
without further action by the Lender.

Interest shall accrue at the rate equal to the lesser of 10% per annum or the maximum rate allowed under the California Constitution.  Said rate shall continue
in effect for the entire period of the Reserve Line of Credit up to the Final Maturity Date.  At no time shall the interest rate, and fees, if applicable, exceed the maximum rate chargeable by
law.

Borrower acknowledges and agrees that the Unpaid Balance is presently due and owing, that the Unpaid Balance is $2,781,561.68 as of April 30, 2014, that the amount under the
revolving line is $1,513,308.61 (not including consulting fees and guarantees as per the last sentence under the "Unpaid Balance" paragraph above), and that there are no
defenses, at law or in equity, to the amount due under this Note as of the date of the execution of this Note.

Lender will receive, concurrently with the execution of this Eight Amended Note, 2,781,562 warrants to acquire shares of Parent's common stock at an exercise price of $0.035 per share
which represents one warrant per dollar outstanding on the Unpaid Balance of the Note as of the renewal date. Such warrants shall be fully vested and be exercisable in cash or in a cashless
exercise at any time prior to their fifth anniversary of issuance, and which shall be non-transferrable without the consent of Parent, which consent is not to be unreasonably withheld.

All payments on this Note are payable at, and all writings respecting the warrants shall be sent to, Lender's accountant at the following address, with a copy to Borrower:  Anderson
Financial, 12021 Wilshire Blvd., Suite 866, Los Angeles, California 90025, Attn: Marilyn Anderson, and RHL Group, PO Box 17034, Beverly Hills, CA 90210, or at such other place as the
Lender or any other holder hereof shall notify Borrower in writing.

All payments received by the Lender on this Note may be applied by Lender as follows: first, to the payment of all fees and expenses owed under this Note or the Security Agreement;
second, to the payment of accrued and unpaid interest then due and owing; and third, to principal or as otherwise indicated by Lender.

This Note may be prepaid in whole or in part, without penalty.  In the event of partial prepayments, the prepayments and proceeds shall be applied as described in the just preceding
paragraph. 

	

PROMISSORY NOTE

	
Page 3 of 8      

At any time or times on or after the date hereof (or, to avoid the provisions of Section 16(b) of the Securities Exchange Act of 1934, as amended, regarding "short swing
profits", six months and one day from the date of the holder's last purchase or sale of equity securities of the Company), the Lender shall be entitled to convert up to Five Hundred
Thousand Dollars ($500,000.00) of the outstanding and unpaid Conversion Amount (as defined below) into fully paid and nonassessable shares of the Parent's Common Stock (the
"Common Stock") at the Conversion Rate (as defined below).  The Company shall not issue any fraction of a share of Common Stock upon any conversion.  If the
issuance would result in the issuance of a fraction of a share of Common Stock, the Company shall round such fraction of a share of Common Stock down to the nearest whole share and the
difference shall remain outstanding as Unpaid Balance under this Note until paid in accordance herewith.  To convert any Conversion Amount into shares of Common Stock on any
date (a "Conversion Date"), the Holder shall deliver to the Company a written notice of conversion so requesting at least ten (10) days prior to the requested Conversion Date (a
"Conversion Request").  Such Conversion Amount shall convert (a "Conversion Event") into fully paid and nonassessable shares of Common Stock at the
Conversion Rate in the manner specified in below.

The number of shares of Common Stock issuable upon conversion of any Conversion Amount pursuant to the foregoing paragraph
shall be determined by dividing (x) such Conversion Amount by (y) the Conversion Price (as defined below) (the "Conversion Rate").

As used herein, the term "Conversion Amount" means the sum of (A) the portion of the Principal to be converted with respect to which this determination is
being made, which shall not exceed $500,000 in the aggregate, and (B) accrued and unpaid Interest with respect to such Principal, and the term "Conversion Price" shall be equal
to $0.02 per share of Common Stock.

On or before a Conversion Event, the Lender shall surrender this Note (or an indemnification undertaking with respect to this Note in the case of its loss,
theft or destruction), duly endorsed, at the Company's principal corporate office, and provide in writing the name or names in which the certificate or certificates for shares of Common Stock
are to be issued.  The Company shall, at its expense and as soon as practicable, thereafter issue and deliver, or cause its transfer agent to issue and deliver, to the Lender, or to the
nominee or nominees of the Lender, a certificate or certificates for the number of shares of Common Stock to which the Lender shall be entitled.  The person or persons entitled to
receive the shares of Common Stock issuable upon a Conversion Event shall be treated for all purposes as the record holder or holders of such shares as of the Conversion Date.  If
this Note is physically surrendered for conversion and the outstanding Principal of this Note is greater than the Principal portion of the Conversion Amount being converted, then the Company
shall as soon as practicable and in no event later than five (5) Trading Days after receipt of this Note, and at its own expense, issue and deliver to the Lender a new Note representing the
outstanding Principal not converted.

Notwithstanding anything else in this Agreement, the entire Unpaid Balance shall be due and owing, without extension on the occurrence of any of the following, unless otherwise agreed
by Lender in writing: (a) a change in ownership or control of Borrower in an amount equal to or

	

PROMISSORY NOTE

	
Page 4 of 8      

greater than one-third (1/3) of outstanding voting stock, other than transactions on a publicly
traded market in the regular course of trading; (b) a transfer of at least one-third (1/3) of the assets of Borrower; (c) a change in the composition of Borrower's Board of Directors, Officers
and/or senior management which is not approved by Lender; (d) Parent or Subsidiary  shall first be the subject of a case pending in any United States Bankruptcy
Court; (e) Parent or Subsidiary shall suffer the appointment of a receiver appointed in any state or federal court action, or other proceeding;  (f) Parent or Subsidiary shall be the subject of any
writ of attachment or writ of execution; (g) Parent or Subsidiary shall not be in full compliance with all of its covenants in prior agreements by August 31, 2014; (h) Parent and Subsidiary shall
fall out of compliance with its covenants on or after  August 31,2014; (i) Borrower shall have less than $200,000 in cash in its bank accounts or such other amount as
necessary to maintain operations, whichever is greater, through the subsequent thirty (30) days on and after August 31, 2014; or (j) Subsidiary and Parent shall not
timely pay any obligations due respecting payroll and all associated payroll taxes at any time during the term of the Note.  Notwithstanding the foregoing sentence, Lender hereby expressly
waives, both now and in the future, any Default or Event of Default under this Note and the Security Agreement that arises from or is related to the Closing (as that term is defined in the
Agreement and Plan of Merger and Reorganization dated November 8, 2008 by and among Borrower, Parent and a wholly-owned merger subsidiary of Parent (the "Merger
Agreement") and the consummation of the transactions described in the Merger Agreement.

The Security Agreement, as amended from time to time, relating to the Original Note, the Amended Note, the Second Amended Note, the Third Amended Note, The Fourth Amended
Note, the Fifth Amended Note, the Sixth Amended Note, the Seventh Amended Note, the Eighth Amended Note, and this Ninth Amended Note shall jointly be referred to as the "Loan
Documents".

Upon the happening of any failure to make any payment under the Loan Documents, or any other "Event of Default" as defined in the Security Agreement, as amended from
time to time, Lender may at its option declare the entire unpaid balance of this Note, together with interest accrued thereon, to be immediately due and payable.  Upon receiving notice of
Default, Borrower will have 15 calendar days to cure such Event of Default.  In the event the Borrower fails to cure the default, the Lender may proceed to exercise any rights or remedies that
it may have under any of the Loan Documents or under this Note or such other rights and remedies which, subject to the provisions of this Note and Loan Documents, the Lender may have at
law, equity or otherwise. In the event of such acceleration, Borrower may discharge its obligations to the Lender by paying the unpaid balance hereof as of the date of such payment, plus
accrued interest and fees, in the manner set forth above.

Upon an Event of Default (as defined in the Security Agreement, as amended from time to time), the interest rate hereunder shall be computed as the higher of: (a) the highest rate then
allowed by law, or (b) the rate described herein.

After default, in addition to principal and accrued interest, the Lender shall be entitled to collect all costs of collection, including, but not limited to, reasonable attorneys' fees incurred in
connection with any of the lender's reasonable collection efforts, whether or not suit on this Note is filed, and all such costs and expenses shall be payable on demand.

	

PROMISSORY NOTE

	
Page 5 of 8      

No failure on the part of the Lender or other holder hereof to exercise any right or remedy hereunder, whether before or after the happening of a default, shall constitute a waiver thereof,
and no waiver of any past default shall constitute waiver of any future default or of any other default.  No failure to accelerate the debt evidenced hereby by reason of default hereunder, or
acceptance of a past due installment or indulgence granted from time to time shall be construed to be a waiver of the right to insist upon prompt payment thereafter, or shall be deemed to be
a novation of this Note or as a reinstatement of the debt evidenced hereby or a waiver of such right of acceleration or any other right, or be construed so as to preclude the exercise of any
right which Lender may have, whether by the laws of the State of California, by agreement or otherwise, and Borrower and each endorser or guarantor hereby expressly waives the benefit of
any statute or rule of law or equity which would produce a result contrary to or in conflict with the foregoing.  This Note may not be changed orally, but only by an agreement in writing signed
by the party against whom such agreement is sought to be enforced.

Borrower and each endorser or guarantor of this Note hereby waives presentment, protest, demand, and diligence, notice of dishonor and notice of nonpayment. 

All agreements between Borrower and Lender, whether now existing or hereafter arising, and whether oral or written, are hereby expressly limited so that in no contingency or event
whatsoever, whether by acceleration of maturity hereof or otherwise, shall the amount paid or agreed to be paid to Lender of the holder hereof, or collected by Lender or such holder for the
use, forbearance or detention of the money to be loaned hereunder or otherwise, or for the payment or performance of any covenant or obligation contained herein, or in any other document
pertaining to the indebtedness evidenced hereby, exceed the maximum amount permissible under governing usury laws as applicable in this transaction,  If, under any circumstances
whatsoever, fulfillment of any provision hereof or of the Loan Documents or any other documents, at the time performance of such provision shall be due, shall involve exceeding the limit of
validity prescribed by law for this transaction, then the obligation to be fulfilled shall be reduced to the limit of such validity; and if under any circumstances Lender or other holder hereof shall
ever receive an amount deemed interest by applicable law, which would exceed the highest lawful rate allowed for this transaction, such amount that would be excessive interest under
governing laws as applicable to this transaction shall be applied to the reduction of the principal amount owing hereunder and not to the payment of interest, or if such excessive interest
exceeds the unpaid balance of principal and such other indebtedness, the excess shall be deemed to have been a payment made by mistake and shall be refunded to Borrower or to any
other person making such payment on Borrower's behalf.  All sums paid or agreed to be paid to the holder hereto for the use, forbearance or detention of the indebtedness of Borrower
evidenced hereby, outstanding from time to time shall, to the extent permitted by governing law, and to the extent necessary to preclude exceeding the limit of validity prescribed by law as
applicable to this transaction, shall be amortized, pro-rated, allocated and spread from the date of disbursement of the proceeds of this Note until payment in full of the loan evidenced hereby
so that the actual rate of interest on account of such indebtedness is uniform throughout the term hereof.  The terms and provisions of this paragraph shall control and supersede every other
provision of all agreements between Borrower, and endorser or guarantor and Lender. 

This Note shall be governed by and construed under the laws of the State of California applicable to contracts made and to be performed entirely in that State without regard to the

	

PROMISSORY NOTE

	
Page 6 of 8      

principles thereof regarding conflict of laws.  Borrower and each endorser or guarantor hereby submits to personal jurisdiction in said State for the enforcement of Borrower's obligations
hereunder, and waives any and all personal rights under the law of the other state to object to jurisdiction within such State for the purposes of litigation to enforce such obligations of
Borrower.  In the event such litigation is commenced, Borrower agrees that service of process may be made and personal jurisdiction over Borrower obtained, by service of a copy of the
summons, complaint and other pleadings required to commence such litigation upon Borrower's appointed agent for service of process in such state with a copy to:

Ingrid Safranek (isafranek@mmrmail.com)

   MMRGlobal, Inc.

   MyMedicalRecords, Inc.

   4401 Wilshire Blvd., Suite 200

   Los Angeles, CA 90010

The holder of this note shall be entitled, without limitation, to all of the rights and remedies of the Lender under the Loan Agreements with respect to this Note.  In the event of any
conflict between the terms and conditions of the Security Agreement and those of this Note, the terms and conditions of this Note shall control.  The obligations of Borrower pursuant to this
Note are secured by the Security Agreement.

Borrower represents that it has obtained all of the corporate authority necessary to execute this Note.

 

 

 

[SIGNATURE PAGE FOLLOWS]

	

PROMISSORY NOTE

	
Page 7 of 8      

IN WITNESS WHEREOF, Borrower has executed this instrument by its duly authorized signatories as of the date first above written.

"Borrower"

MyMedicalRecords, Inc., a Delaware corporation ("Subsidiary")

Name: Ingrid Safranek

Title: CFO

Signature: ______________________________

Date: July 10, 2014

MMRGlobal, Inc., a Delaware corporation ("Parent")

Name: Ingrid Safranek

Title: CFO

Signature: ______________________________

Date: July 10, 2014

The RHL Group, Inc. ("Lender")

Name: Robert H. Lorsch

Title: CEO

Signature: ______________________________

Date: July 10, 2014

	

PROMISSORY NOTE

	
Page 8 of 8Q2 2014 Exhibit 10.2

Exhibit 10.2

CONFIDENTIAL PORTIONS OF THIS AGREEMENT HAVE BEEN OMITTED BASED UPON A

                   REQUEST FOR CONFIDENTIAL TREATMENT PURSUANT TO RULE 24b-2 OF THE

                   SECURITIES EXCHANGE ACT OF 1934 AND HAVE BEEN SEPARATELY FILED

                   WITH THE SECURITIES AND EXCHANGE COMMISSION

PATENT LICENSE AGREEMENT

This Patent License Agreement (hereinafter, the "Agreement"), is entered into as of June 30, 2014 (the "Effective Date"),
by MyMedicalRecords, Inc., a corporation organized and existing under the laws of Delaware (hereinafter "Licensor") and Salutopia, Inc., a corporation organized and
existing under the laws of Texas (hereinafter "Licensee").

WHEREAS, Licensor is the owner of all right, title and interest in certain "Licensed Patents" as that term is defined in Section 1.1(a) of this Agreement;

WHEREAS, Licensee is a healthcare software innovations company, providing agnostic, interoperative, single point-of-access solutions that make communication
among providers, patients and insurance companies; and

WHEREAS, Licensor is willing to grant to Licensee and Licensee desires to acquire from Licensor a non-exclusive license to the Licensed Patents and the right to
sell Licensor's products as defined below in the territories and on the terms and conditions set forth in this Agreement;

NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth herein, the Parties hereby agree as follows:

1.      DEFINITIONS AND INTERPRETATION 

1.1   In this Agreement, the following words and phrases shall have the following meanings:  

(a)   "Licensed Patents" means all rights related to Health IT patents owned by Licensor as of the date of this Agreement or at any time during the
term thereafter, including but not limited to U.S. Patent Nos. 8,117,045; 8,117,646; 8,121,855; 8,301,466; 8,321,240; 8,352,287; 8,352,288; 8,498,883; 8,626,532; 8,645,161; and 8,725,537,
and other patents to be issued pursuant to pending applications filed by Licensor in the United States, and all divisions, continuations, reissues, and extensions thereof.  The Licensed Patents
do not include any other patents owned by Licensor or its related entities, including biotechnology patents U.S. Patent No. 8,133,486 and U.S. Patent No. 8,114,404. 

(b)   "Licensor's Product(s)" means Licensor's MyMedicalRecords, MMRPro and MyESafeDepositBox branded or private labeled products or
services or any proprietary features of the Licensor's Products which Licensee acknowledges use or incorporate, in whole or in part, the Licensed Patents. 

Patent License Agreement 

        Page 1 of 13 

        Initial _____             Initial _____          

_____________________________________________________________________________________________________

[***]: Certain confidential information contained in this document marked with three asterisks has been omitted and filed separately
   with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended .
 

CONFIDENTIAL PORTIONS OF THIS AGREEMENT HAVE BEEN OMITTED BASED UPON A

                   REQUEST FOR CONFIDENTIAL TREATMENT PURSUANT TO RULE 24b-2 OF THE

                   SECURITIES EXCHANGE ACT OF 1934 AND HAVE BEEN SEPARATELY FILED

                   WITH THE SECURITIES AND EXCHANGE COMMISSION

(c)   "Licensed Products and Services" and/or "Licensed Products" means Licensee's agnostic aggregation, integration,
normalizing, refactoring, and distribution of the patient presentation layer, sometimes referred to as the "Salutopia patient portal." 

(d)   "Licensee Clients" means any client(s) who pays to use Licensee's solution(s), provided Licensee pays the Royalty on Licensee Clients to
Licensor. In the event that Licensee Clients require an extension of the use of the service including that Patent license as described in this Agreemernt, additional written permission from
Licensor will be required as an amendment to this Agreement. Licensor agrees it will not directly or indirectly (except through Licensee) solicit business from any said client(s). Similarly,
Licensee shall submit a monthly report of the then-current sales pipeline to establish such potential client(s) who likewise shall be considered exclusive to Licensee with the same protections
as current client(s). Licensee shall have 90 days from the original submission of each such pipeline report to close new entries added to each such report. The 90-day period can be extended
based on the then-current position of the sales process as will be clearly identified in each such sales pipeline report.  

(e)   "Gross Sales" means the aggregate compensation collected by the Licensee, or its subsidiaries or related entities, without a reduction for
taxes, transportation, returns, depreciation or other expenses. 

(f)   "Party" or "Parties" means each of the parties to this Agreement. 

(g)   "Territory" means the United States of America, including any and all of its territories and possessions. 

1.2   In this Agreement, except as otherwise expressly provided or as the context otherwise requires: 

(a)   the symbol § followed by a number or some combination of numbers and letters refers to the section, paragraph, subparagraph, clause or sub-clause of this
Agreement so designated; 

(b)   headings are solely for convenience of reference and are not intended to be complete or accurate descriptions of content or to be guides to interpretation of this
Agreement or any part of it; 

(c)   the word "including", when following a general statement or term, is not to be construed as limiting the general statement or term to any specific item or
matter set forth or to similar items or matters, but rather as permitting the general statement or term to refer also to all other items or matters that could reasonably fall within its broadest
possible scope; 

(d)   a reference to currency means United States currency;

Patent License Agreement 

        Page 2 of 13 

        Initial _____             Initial _____          

_____________________________________________________________________________________________________

[***]: Certain confidential information contained in this document marked with three asterisks has been omitted and filed separately
   with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended .
 

CONFIDENTIAL PORTIONS OF THIS AGREEMENT HAVE BEEN OMITTED BASED UPON A

                   REQUEST FOR CONFIDENTIAL TREATMENT PURSUANT TO RULE 24b-2 OF THE

                   SECURITIES EXCHANGE ACT OF 1934 AND HAVE BEEN SEPARATELY FILED

                   WITH THE SECURITIES AND EXCHANGE COMMISSION

(e)   a reference to an entity includes any successor to that entity; and 

(f)   a word importing the gender includes the feminine and neuter, a word in the singular includes the plural, a word importing a corporate entity includes an individual,
and vice versa. 

2.      LICENSE GRANT 

2.1 License Grant.  

Licensor, on behalf of itself and its legal successors, heirs and assigns, hereby grants to Licensee, a limited, royalty-bearing license under the Licensed Patents to
manufacture, make, have made, use, lease, sell, offer to sell, rent, import, export, practice, license or otherwise transfer any Licensed Products and to sell Licensor's Products. 

2.2Reserved Rights.  

Any and all rights not explicitly granted to Licensee in Section 2.1 are reserved by Licensor. Licensor does not confer upon Licensee the right to grant or otherwise
transfer any rights under the Licensed Patents to any other third party individual or entity for any purpose, except as set out in Section 2.1 without written permission of Licensor.  

2.3Licensee Liable for Obligations of Related Entities.  

Licensee is and shall remain primarily liable to Licensor for all of its Related Entities, including any affiliates, obligations, covenants, representations and performance
under each and every term and condition of this Agreement.

2.4Marking. 

To the extent reasonably feasible, Licensee agrees to mark every Licensed Product sold by it in the Territory under this Agreement in accordance with 35 U.S.C.
287.  Licensee shall provide on or in conjunction with Licensed Products a written notification specifically stating that the Licensed Product(s) are sold under a non-exclusive license with
Licensor and shall list the Licensed Patents or, as an alternative to listing the Licensed Patents, refer to a web site containing such a list. 

3.      ROYALTY 

3.1Ongoing Royalties. 

[***] 

Patent License Agreement 

        Page 3 of 13 

        Initial _____             Initial _____          

_____________________________________________________________________________________________________

[***]: Certain confidential information contained in this document marked with three asterisks has been omitted and filed separately
   with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended .
 

CONFIDENTIAL PORTIONS OF THIS AGREEMENT HAVE BEEN OMITTED BASED UPON A

                   REQUEST FOR CONFIDENTIAL TREATMENT PURSUANT TO RULE 24b-2 OF THE

                   SECURITIES EXCHANGE ACT OF 1934 AND HAVE BEEN SEPARATELY FILED

                   WITH THE SECURITIES AND EXCHANGE COMMISSION

[***]

[***]

3.2Payments.

Licensee shall pay Licensor the fees set forth in  3.1 on a monthly basis for each month the Agreement is in effect.  Payment of the fees is due within 20 days
following the last day of each month based on cash collections.  All payments due under this Agreement shall be made by wire transfer, pursuant to instructions to be provided in writing by
the Parties.

3.3Failure to Timely Pay.

If Licensee or Licensor fails to make any payment that may be required under this Agreement within the time period prescribed for such payment, then the unpaid
amount shall bear interest at the rate of [***], or other authorized statutory rate, if higher, from the date when the payment was due until payment in full, with interest, is made.

3.4Royalty Report.

Licensee shall provide a quarterly Royalty Report showing the [***], payable, and paid during each quarter.  The Royalty Report is due within 15 days of the end of the
quarter.

3.5   Records.  

Licensee shall keep records of the Gross Sales and number of Licensed Products and Licensor's Product sold pursuant to this Agreement in sufficient detail to enable
the royalty payment to Licensor to be recalculated, audited, and otherwise verified. 

3.6   Annual Inspection.  

Licensee shall allow Licensor's representative one annual inspection, during regular business hours or at such other times as may be mutually agreeable, to
inspect Licensee's books and records to the extent reasonably necessary to determine Licensee's compliance with the terms of this Agreement.

3.6   Penalty.  

If the Licensor determines through an annual inspection that the Licensor was undercompensated as required by this Agreement, then the Licensee shall pay to
the Licensor a penalty fee equal to [***]; provided, however, such penalty fee shall only be required where such undercompensation can be shown to be the result of willful withholding of such amounts

Patent License Agreement 

        Page 4 of 13 

        Initial _____             Initial _____          

_____________________________________________________________________________________________________

[***]: Certain confidential information contained in this document marked with three asterisks has been omitted and filed separately
   with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended .
 

CONFIDENTIAL PORTIONS OF THIS AGREEMENT HAVE BEEN OMITTED BASED UPON A

                   REQUEST FOR CONFIDENTIAL TREATMENT PURSUANT TO RULE 24b-2 OF THE

                   SECURITIES EXCHANGE ACT OF 1934 AND HAVE BEEN SEPARATELY FILED

                   WITH THE SECURITIES AND EXCHANGE COMMISSION

due rather than unintentional error in calculation. The Licensee shall still be obligated to pay full compensation as required under the Agreement. 

4.      RELEASE 

4.1   Prior Infringement.  

As of the Effective Date, and by the operation of this Agreement, Licensor hereby fully, finally and forever releases, relinquishes, quitclaims and discharges all claims
that Licensor had or now has against Licensee or its past and present directors and officers, and its predecessors, successors and assigns, whether known or unknown, arising from or in
connection with the manufacture (including practicing methods, processes and procedures), use, lease, license, sale, offer for sale, market, distribution, exportation or importation of the
Licensed Products from the beginning of time to the Effective Date of this Agreement.

5.      TERM & TERMINATION 

5.1   Term. 

The term of this Agreement is [***] years beginning on the Effective Date (the "Initial Term").  Upon the expiration of the Initial Term, the Agreement will
automatically renew for an additional [***] years (each such renewed period being a "Renewed Term"), subject to the right of each Party to terminate as set forth below.

5.2   Licensor Termination. 

Licensor may terminate this Agreement effective immediately upon its giving written notice in the event of any of the following: (a) liquidation of Licensee; (b)
insolvency or bankruptcy of Licensee, whether voluntary or involuntary; or (c) appointment of a trustee or receiver for Licensee.  Licensor also may terminate this Agreement at the end of the
then current Renewal Term by providing 60 days' written notice to Licensee a) prior to the expiration of the then current Renewal Term, or b) upon material breach of this Agreement and
failure to cure such breach within 30 days.

5.3   Licensee Termination. 

Licensee may terminate this Agreement effective immediately upon its giving written notice in the event of any of the following: (a) liquidation of Licensor; (b)
insolvency or bankruptcy of Licensor, whether voluntary or involuntary; or (c) appointment of a trustee or receiver for Licensor.  Licensee also may terminate this Agreement at the end of the
then current Renewal Term by providing 60 days' written notice to Licensor a) prior to the expiration of the then current Renewal Term, or b) upon material breach of this Agreement and
failure to cure such breach within 30  days.

Patent License Agreement 

        Page 5 of 13 

        Initial _____             Initial _____          

_____________________________________________________________________________________________________

[***]: Certain confidential information contained in this document marked with three asterisks has been omitted and filed separately
   with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended .
 

CONFIDENTIAL PORTIONS OF THIS AGREEMENT HAVE BEEN OMITTED BASED UPON A

                   REQUEST FOR CONFIDENTIAL TREATMENT PURSUANT TO RULE 24b-2 OF THE

                   SECURITIES EXCHANGE ACT OF 1934 AND HAVE BEEN SEPARATELY FILED

                   WITH THE SECURITIES AND EXCHANGE COMMISSION

5.4   Cease and Desist. 

Subject to  6, upon termination of this Agreement, Licensee shall cease any and all use of the Licensor's Products and any and all activities under the Licensed
Patents, including any Licensed Products that include the Patented Technology.

5.5   Expiration of Licensed Patents. 

Unless earlier terminated as herein provided, this Agreement shall expire simultaneously with the last to expire of the Licensed Patents.

Should any of the Licensed Patents be revoked, nullified, or otherwise deemed unlawful or untenable, then this Agreement shall immediately terminate due to the
interrelatedness of each of the Licensed Patents.

Licensor hereby holds harmless, releases, and will defend Licensee and its clients against any and all liability, to the fullest extent of the law should any of the
Licensed Patents cause rise to litigation or challenge of any kind where such claim of liability is only based upon an allegation that the Licensed Patents are not valid. It is the responsibility of
the Licensor to maintain the legal validity of the patents and defend any such challenge.  

5.6   [***] 

[***]

5.7   Payment Due Upon Termination. 

Upon termination of this Agreement for any reason whatsoever, Licensee shall report and pay to Licensor within thirty (30) days of such termination, all unpaid
amounts due and owing Licensor, including, but not limited to, fees, payments, royalties, reimbursements, interest, and other forms of consideration.

6.      CONTINUING OBLIGATIONS 

6.1   Pre-Termination Obligations. 

Termination of the Agreement will not affect any pre-termination obligations of either Party under the Agreement and any such termination is without prejudice to
the enforcement of any undischarged obligations existing at the time of termination. 

6.2   Effect on End-User Sublicenses. 

End-user sublicenses properly granted pursuant to this Agreement shall be terminated concurrent with the termination of this Agreement.

Patent License Agreement 

        Page 6 of 13 

        Initial _____             Initial _____          

_____________________________________________________________________________________________________

[***]: Certain confidential information contained in this document marked with three asterisks has been omitted and filed separately
   with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended .
 

CONFIDENTIAL PORTIONS OF THIS AGREEMENT HAVE BEEN OMITTED BASED UPON A

                   REQUEST FOR CONFIDENTIAL TREATMENT PURSUANT TO RULE 24b-2 OF THE

                   SECURITIES EXCHANGE ACT OF 1934 AND HAVE BEEN SEPARATELY FILED

                   WITH THE SECURITIES AND EXCHANGE COMMISSION

6.3   Return of Materials. 

All of Licensor's trademarks, marks, trade names, patents, copyrights, trade secrets, confidential information, designs, drawings, formulas or other data,
photographs, samples, literature, and sales aids of every kind will remain the property of Licensor.  Within 30 days after the termination of this Agreement, Licensee will prepare all such items
in its possession for either return or destruction (at Licensor's option) at Licensor's expense.  Licensee will not make or retain any copies of any confidential items or information which may
have been entrusted to it.  Effective upon the termination of this Agreement for any reason, Licensee will cease to use all trademarks, product names and trade names of Licensor.

All of Licensee's trademarks, marks, trade names, patents, copyrights, trade secrets, confidential information, designs, drawings, formulas or other data, photographs,
samples, literature, and sales aids of every kind will remain the property of Licensee.  Within 30 days after the termination of this Agreement, Licensor will prepare all such items in its
possession for either return or destruction (at Licensee's option) at Licensee's expense.  Licensor will not make or retain any copies of any confidential items or information which may have
been entrusted to it.  Effective upon the termination of this Agreement for any reason, Licensor will cease to use all trademarks, product names and trade names of Licensee.

   

   

   

Patent License Agreement 

        Page 7 of 13 

        Initial _____             Initial _____          

_____________________________________________________________________________________________________

[***]: Certain confidential information contained in this document marked with three asterisks has been omitted and filed separately
   with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended .
 

CONFIDENTIAL PORTIONS OF THIS AGREEMENT HAVE BEEN OMITTED BASED UPON A

                   REQUEST FOR CONFIDENTIAL TREATMENT PURSUANT TO RULE 24b-2 OF THE

                   SECURITIES EXCHANGE ACT OF 1934 AND HAVE BEEN SEPARATELY FILED

                   WITH THE SECURITIES AND EXCHANGE COMMISSION

7.      GENERAL PROVISIONS 

7.1   Survival of Certain Terms. 

The rights, obligations and terms specified in    3, 4, 6, and 7 of this Agreement, and any other obligations which by its nature ought to survive, shall survive its
termination or expiration.

7.2   No Warranties. 

Nothing in this Agreement shall be construed as a warranty or representation by Licensor that (i) any of the Licensed Patents are valid, enforceable or infringed by
any particular product or service, or (ii) that anything made, used, sold, imported or otherwise disposed of under the license granted in this Agreement is or will be free from infringement of
any patents or other rights owned by any third party.  WITHOUT LIMITING THE FOREGOING, LICENSOR MAKES NO WARRANTIES, EXPRESS OR IMPLIED, BY STATUTE OR
OTHERWISE, REGARDING THE LICENSED PATENTS, MATERIALS LICENSED TO OR PROVIDED TO LICENSEE HEREUNDER, AND SPECIFICALLY DISCLAIMS ALL WARRANTIES,
EXPRESS, IMPLIED OR STATUATORY INCLUDING WITHOUT LIMITATION THE IMPLIED WARRANTIES OF TITLE, NON-INFRINGEMENT, FITNESS FOR A PARTICULAR PURPOSE
AND MERCHANTABILITY.

7.3   Limitation of Liability. 

LICENSEE AGREES THAT LICENSOR WILL NOT BE LIABLE FOR ANY INDIRECT, SPECIAL, INCIDENTAL, OR CONSEQUENTIAL DAMAGES OF ANY KIND
(INCLUDING WITHOUT LIMITATION ANY LOST PROFITS) REGARDLESS OF THE FORM OF ACTION WHETHER IN CONTRACT, TORT (INCLUDING NEGLIGENCE), STRICT
SOFTWARE LIABILITY, OR OTHERWISE, EVEN IF LICENSEE HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.  IN NO EVENT SHALL LICENSOR'S LIABILITY TO
LICENSEE EXCEED AMOUNTS PAID BY LICENSEE UNDER THIS AGREEMENT EXCEPT AS OTHERWISE DELINEATED IN THIS AGREEMENT.  THE PARTIES ACKNOWLEDGE AND
AGREE THAT THIS SECTION 7.3 IS AN ESSENTIAL ELEMENT OF THE AGREEMENT AND THAT IN ITS ABSENCE, THE ECONOMIC TERMS OF THIS AGREEMENT WOULD BE
SUBSTANTIALLY DIFFERENT.

7.4   Independent Companies. 

The relationship of Licensor and Licensee established by the Agreement is that of independent contractors, and nothing contained in this Agreement will be construed to create a

Patent License Agreement 

        Page 8 of 13 

        Initial _____             Initial _____          

_____________________________________________________________________________________________________

[***]: Certain confidential information contained in this document marked with three asterisks has been omitted and filed separately
   with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended .
 

CONFIDENTIAL PORTIONS OF THIS AGREEMENT HAVE BEEN OMITTED BASED UPON A

                   REQUEST FOR CONFIDENTIAL TREATMENT PURSUANT TO RULE 24b-2 OF THE

                   SECURITIES EXCHANGE ACT OF 1934 AND HAVE BEEN SEPARATELY FILED

                   WITH THE SECURITIES AND EXCHANGE COMMISSION

partnership, joint venture or agency relationship between the Parties, and, notwithstanding anything else herein, neither Party will have the right to incur (and will not
attempt to incur) any obligation or liability on behalf of the other Party.  

7.5   [***] 

[***]

7.6   Rightful Participation; Conformance to Law. 

The Parties represent that their entry into this Agreement is rightful and does not violate any other agreement to which they are a party.  Both Parties represent
that their business conduct in performing under this Agreement will conform to all applicable and valid laws, rules and regulations.

7.7   Severability. 

Each provision of this Agreement is intended to be severable, and the unenforceability or invalidity of any provision under any applicable law will not affect the
enforceability or validity of the remainder of this Agreement in so far as such law is applicable, or of this entire Agreement in so far as such law is not applicable.

7.8   Waiver. 

The failure of a Party at any time to enforce any provisions of this Agreement or to exercise any right or remedy shall not be construed to be a waiver of such
provisions or of such rights or remedy or the right of such Party thereafter to enforce each and every provision, right or remedy.

The waiver of a specific breach hereunder may be effectuated only by a written document, signed by the waiving Party, and delivered to the breaching Party.  Such
formal waiver shall not constitute a waiver of any other breach.

7.9   Governing Law. 

This Agreement is and will be deemed to be made in the State of California and for all purposes will be governed exclusively by and construed and enforced in
accordance with the laws prevailing in the State of California and the laws of the United States, and the rights and remedies of the Parties will be determined in accordance with those laws.

7.10   Binding Arbitration.   

Any controversy or claim arising out of or relating to this contract, or the breach thereof, shall be settled by binding arbitration administered by the American Arbitration Association in

Patent License Agreement 

        Page 9 of 13 

        Initial _____             Initial _____          

_____________________________________________________________________________________________________

[***]: Certain confidential information contained in this document marked with three asterisks has been omitted and filed separately
   with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended .
 

CONFIDENTIAL PORTIONS OF THIS AGREEMENT HAVE BEEN OMITTED BASED UPON A

                   REQUEST FOR CONFIDENTIAL TREATMENT PURSUANT TO RULE 24b-2 OF THE

                   SECURITIES EXCHANGE ACT OF 1934 AND HAVE BEEN SEPARATELY FILED

                   WITH THE SECURITIES AND EXCHANGE COMMISSION

accordance with the Expedited Procedures of the Complex Commercial Arbitration Rules, including the Emergency Interim Relief Procedures, and shall take place in Los
Angeles, California.  The judgment on the award rendered by the arbitrator(s) may be entered in any court having jurisdiction thereof, including either the courts of the State of California or the
appropriate U.S. Federal Court therein, to which the Parties hereby irrevocably consent and submit to the venue and jurisdiction.

7.11   Assignment. 

Niether party shall assign any right, benefit or interest in this Agreement without the written consent of the other party, and any purported assignment without such
consent will be void.

7.12   Binding Effect. 

This Agreement will inure to the benefit of and be binding upon the respective successors and permitted assigns of the Parties.

7.13   Notices. 

Any notice or other communication provided for in this Agreement shall be in writing and shall be sent by nationally recognized courier or messenger (with
confirmation of receipt), or by registered or certified US Mail, or sent by facsimile transmission (as verified by a transmission report), provided, that, any notice by facsimile shall be
concurrently sent via one of the other methods as well, as the case may be, to the addresses of the parties set out below, until a notice of change of address by such party is served in the
manner provided for in this section, as follows:

If to Licensor: 

                           MyMedicalRecords, Inc.

                           Attn:  Robert Lorsch, Chief Executive Officer

                           4401 Wilshire Boulevard

                           Los Angeles, California 90010

                           Telefacsimile: (206) 374-6136

If to Licensee: 

Salutopia

                           Attn:  Jeffrey Renton, Chief Executive Officer

                           13831 Northwest Freeway, Suite 215

                           Houston, Texas 77040

                           Telefacsimile: (888) 467-6917

Patent License Agreement 

        Page 10 of 13 

        Initial _____             Initial _____          

_____________________________________________________________________________________________________

[***]: Certain confidential information contained in this document marked with three asterisks has been omitted and filed separately
   with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended .
 

CONFIDENTIAL PORTIONS OF THIS AGREEMENT HAVE BEEN OMITTED BASED UPON A

                   REQUEST FOR CONFIDENTIAL TREATMENT PURSUANT TO RULE 24b-2 OF THE

                   SECURITIES EXCHANGE ACT OF 1934 AND HAVE BEEN SEPARATELY FILED

                   WITH THE SECURITIES AND EXCHANGE COMMISSION

7.14   Entire Agreement.   

This Agreement constitutes the entire agreement between the Parties and supersedes every previous agreement, communication, expectation, negotiation,
representation or understanding, whether oral or written, express or implied, statutory or otherwise, between the Parties with respect to the primary subject matter of this Agreement.

7.15   Amendment. 

This Agreement may not be amended except in writing executed by each of the Parties.

7.16   Confidentiality of Terms. 

This Agreement is confidential. The Parties shall not disclose to any other person the terms of this Agreement except with the written
consent of the other. The only exceptions to the confidentiality provisions in this section are that disclosure to other persons of the terms of this Agreement is permitted:

a) Where the prior written consent of the other party has been obtained;

b) To a party's executive officers, board of directors, or its employees who need to know such information in order to perform their job functions, in each case such
persons being bound by confidentiality agreements to prevent disclosure of confidential information such as this Agreement;

c) To a party's own attorneys, tax consultants, tax advisors, accountants, other financial advisors or existing or prospective insurance providers, who is/are consulted
by such party for legal, tax reporting, tax planning, financial planning, advisory, or insurance purposes;

d) Where required in response to an order or other process of a court or administrative agency of competent jurisdiction, including without limitation, any third party
subpoena, so long as the party required to respond notifies the other party in a timely fashion so that other party may object, seek to restrict disclosure, or pursue other alternatives in seeking
to restrict disclosure of the Agreement; or

e) For purposes of enforcement in court of any legal proceeding pertaining to the Agreement or matters pertaining to the Agreement.

Patent License Agreement 

        Page 11 of 13 

        Initial _____             Initial _____          

_____________________________________________________________________________________________________

[***]: Certain confidential information contained in this document marked with three asterisks has been omitted and filed separately
   with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended .
 

CONFIDENTIAL PORTIONS OF THIS AGREEMENT HAVE BEEN OMITTED BASED UPON A

                   REQUEST FOR CONFIDENTIAL TREATMENT PURSUANT TO RULE 24b-2 OF THE

                   SECURITIES EXCHANGE ACT OF 1934 AND HAVE BEEN SEPARATELY FILED

                   WITH THE SECURITIES AND EXCHANGE COMMISSION

Except as described in subsections a) through e), above, when describing the nature or terms of this Agreement, a party is allowed only to state that: (1) the
Agreement was made by mutual consent and the terms are confidential; and (2) the Party is not at liberty to provide further information.

Notwithstanding this section 7.16, to the extent that SEC requirements call for any portion of this transaction to be disclosed, the Parties agree to cooperate in seeking
confidential treatment of this Agreement and any exhibits, amendments, and/or addendums, as may be applicable.

Except as provided above, the Parties specifically agree not to share with any third parties any documents or materials that may have been provided between the
parties during discussions or negotiations leading to the drafting and culmination of this Agreement.

7.17   Further Assurances. 

Each Party will, at such Party's own expense and without expense to the other Party, execute and deliver such further agreements and other documents and do
such further acts and things as the other Party reasonably requests to evidence, carry out or give full force and effect to the intent of this Agreement.

7.18   Counterparts. 

This Agreement and any other writing delivered pursuant hereto may be executed in any number of counterparts, in original form or by electronic facsimile, with
the same effect as if all Parties to this Agreement or such other writing had signed the same document, and all counterparts will be construed together and constitute one and the same
instrument.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

   

   

Patent License Agreement 

        Page 12 of 13 

        Initial _____             Initial _____          

_____________________________________________________________________________________________________

[***]: Certain confidential information contained in this document marked with three asterisks has been omitted and filed separately
   with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended .
 

CONFIDENTIAL PORTIONS OF THIS AGREEMENT HAVE BEEN OMITTED BASED UPON A

                   REQUEST FOR CONFIDENTIAL TREATMENT PURSUANT TO RULE 24b-2 OF THE

                   SECURITIES EXCHANGE ACT OF 1934 AND HAVE BEEN SEPARATELY FILED

                   WITH THE SECURITIES AND EXCHANGE COMMISSION

IN WITNESS WHEREOF, the Parties have executed this Agreement as of the Effective Date.  

	
MyMedicalRecords, Inc.

/s/ Ingrid Safranek

Ingrid Safranek - Chief Financial Officer

Date: June 30, 2014

	
Salutopia

/s/ Jeffrey Renton

 Jeffrey Renton - Chief Executive Officer

Date: June 30, 2014

   

   

Patent License Agreement 

        Page 13 of 13

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00234-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00234-of-00352.parquet"}]]